Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Relatives of SARS-CoV-2 may pose a health threat for years to come

Coronaviruses are zoonotic viruses that jump from animals to humans and cause infection. There are many types of common human coronaviruses, which usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. Most people get infected with one or more of coronavirus types 229E, NL63, OC43, and HKU1 at some point in their lives.

29 Jul 2020

The toll that COVID-19 takes on the heart

Now, two new studies describe the toll that COVID-19 takes in the heart, increasing the risk of long-term damage even after patients recover. These studies also show that heart damage can even occur in people who did not have severe illness that required hospitalization.

29 Jul 2020

Loss of smell in COVID-19 explained by scientists

Now, a team of researchers at Harvard Medical school says they have found the reason why some people who get COVID-19 experience loss of smell.

29 Jul 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

People with SARS-CoV-2 most infectious in days 0-5, no evidence of transmission after day 9

A study conducted by researchers in the UK and Italy suggests that individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are probably at their most infectious during the first week of illness.

29 Jul 2020

Inconsistent SARS-CoV-2 antibody results in nephrology workers

Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.

29 Jul 2020

Platelet hyperreactivity, a unique feature of COVID-19

A new study by Irish researchers and published in the preprint server medRxiv in July 2020 reports a bidirectional relationship between COVID-19 and coagulation abnormalities.

29 Jul 2020

Exciting cost-effective SARS-CoV-2 vaccine candidate using Newcastle disease

Experts warn that the world may see repeated waves of the COVID-19 pandemic. However, scientists around the world are working hard to create a protective vaccine or antiviral, which could help to reduce the number of deaths and cases the next time around.

29 Jul 2020

Case Fatality Rate alone may be a misleading measure of overall COVID-19 mortality

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 16.67 million individuals and caused over 659,000 deaths around the world. Commonly the deadly virus and its impact are measured by the case fatality ratio (CFR).

29 Jul 2020

Mental health problems peak alongside COVID-19 in Australia

A new study has found that during the peak of the outbreak in Australia, the rates of psychological distress, anxiety, and depression symptoms rose among adults. The study is published in the latest issue of the journal PLOS ONE.

29 Jul 2020

Sniffer dogs detect COVID-19 infections with 94 percent accuracy

Dogs have an acute sense of smell. They have up to 300 million olfactory receptors in their noses, compared to six million in humans, making their smell receptors up 10,000 to 100,000 more powerful than humans.

28 Jul 2020

Which face masks works best against COVID-19?

Wearing face masks is widely recommended as the coronavirus disease (COVID-19) continues to ravage across the globe. The pandemic has now topped more than 16.66 million cases, with a staggering death toll of at least 659,000.

28 Jul 2020

Basigin/CD147 discarded as an accessory SARS-CoV-2 binding receptor

By using specialized assays customized to detect specific receptor interactions, researchers from the Wellcome Sanger Institute in Cambridge UK find no evidence for direct binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to a transmembrane glycoprotein known as basigin.

28 Jul 2020

Emergent SARS-CoV-2 D614G spike mutation more infective due to "open" morphology

Researchers from the Los Alamos National Laboratory and Duke Human Vaccine Institute & Department of Surgery demonstrated that globally prevalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the amino acid substitution D614G in the spike protein is much more infective due to profitable binding encounters with the host receptors.

28 Jul 2020

Pitt collaborative receives $7 million to evaluate convalescent plasma therapy for COVID-19

A team of University of Pittsburgh, Michigan Medicine, Medical University of South Carolina and Stanford Medicine. researchers recently were awarded funds from the National Heart, Lung, and Blood Institute in collaboration with the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, totaling more than $7 million to collaboratively study the role of convalescent plasma in mitigating symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

28 Jul 2020

Cat catches coronavirus from owners

Cases of pet animals contracting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported since the coronavirus disease (COVID-19) first emerged. Now, a pet cat has become the first animal in Britain to test positive after contracting the virus from its owners.

28 Jul 2020

Moderna coronavirus vaccine candidate moves to phase 3 with 30,000 participants

The world’s most significant coronavirus disease (COVID-19) vaccine study is underway in the United States, with a planned 30,000 volunteers. The phase 3 clinical trial aims to examine the efficacy and safety of the candidate vaccine developed by the National Institutes of Health and Moderna Inc.

28 Jul 2020